<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Baclofen: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Baclofen: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Baclofen: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9062" href="/d/html/9062.html" rel="external">see "Baclofen: Drug information"</a> and <a class="drug drug_patient" data-topicid="11129" href="/d/html/11129.html" rel="external">see "Baclofen: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708644"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Abrupt withdrawal (injection): </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, which in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death.</p>
<p style="text-indent:-2em;margin-left:2em;">Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Advise patients and caregivers of the importance of keeping scheduled refill visits and educate them on the early symptoms of baclofen withdrawal. Give special attention to patients at apparent risk (eg, spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional postimplant clinician and patient information.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F138898"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fleqsuvy;</li>
<li>Gablofen;</li>
<li>Lioresal;</li>
<li>Lyvispah;</li>
<li>Ozobax DS;</li>
<li>Ozobax [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866028"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Baclofen;</li>
<li>Baclofen-10;</li>
<li>Baclofen-20;</li>
<li>Lioresal DS [DSC];</li>
<li>Lioresal Intrathecal;</li>
<li>Lioresal [DSC];</li>
<li>MYLAN-Baclofen;</li>
<li>PMS-Baclofen;</li>
<li>RIVA-Baclofen</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056749"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Skeletal Muscle Relaxant, Nonparalytic</span></li></ul></div>
<div class="block dop drugH1Div" id="F138920"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Gradual dose reduction is advised unless discontinuation is due to significant adverse effects or overdose-related emergencies; chronic oral baclofen therapy should be discontinued slowly (eg, over at least 1 to 2 weeks or longer if withdrawal symptoms occur) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20101040','lexi-content-ref-CSM.1997','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20101040','lexi-content-ref-CSM.1997','lexi-content-ref-Manu.1'])">Ref</a></span>). Abrupt discontinuation of oral or intrathecal baclofen may result in severe adverse effects, including multiple organ system failure and death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Baclofen is available as both an oral solution and oral suspension; concentration varies by product; use extra caution during product selection and preparation and verify correct product/concentration is chosen.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9696f64-895f-4d97-bbb7-9feeb1ed243d">Spasticity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spasticity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral:</i>
<b>Note:</b> Dose-related side effects (eg, sedation) may be minimized by slow titration; lower initial doses than described below (2.5 to 10 mg administered daily) may be used with subsequent titration to 8 hourly doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17044900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17044900'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥4 months and Children &lt;2 years: Very limited data available: Oral: Usual dose: 10 to 20 mg/day in divided doses every 8 hours; begin at low end of range and titrate dose to patient response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17156708']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17156708'])">Ref</a></span>); titration intervals of every 7 days have been used in pediatric patients ≥2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27504360','lexi-content-ref-17044900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27504360','lexi-content-ref-17044900'])">Ref</a></span>). Maximum daily dose: 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17156708']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17156708'])">Ref</a></span>). Dosing based on a retrospective study of 87 patients (age 9 ± 6 years; range: 0.4 to 23.5 years) with spasticity due to cerebral palsy or traumatic brain injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17156708']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17156708'])">Ref</a></span>). <b>Note:</b> To minimize dose-related side effects (eg, sedation), lower initial doses (ie, 2.5 mg once to 3 times daily) may be considered and have been reported in pediatric patients &gt;2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27504360','lexi-content-ref-17044900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27504360','lexi-content-ref-17044900'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 7 years: Limited data available: Oral: Initial: 2.5 mg 3 times daily; titrate dose by 5 mg increments at weekly intervals to patient response; usual dose: 20 to 40 mg/day. Maximum daily dose: 60 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27504360','lexi-content-ref-17156708','lexi-content-ref-338390','lexi-content-ref-17044900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27504360','lexi-content-ref-17156708','lexi-content-ref-338390','lexi-content-ref-17044900'])">Ref</a></span>). <b>Note:</b> Initial doses of 5 to 10 mg/day divided every 8 hours and more frequent titration intervals (ie, every 3 days) have also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-338390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-338390'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥8 years and Adolescents: Limited data available in children &lt;12 years: Oral: Initial: 5 mg 3 times daily; titrate dose to patient response every 3 to 7 days to usual dose of 30 to 40 mg/day; some patients ≥12 years may require every-6-hour dosing; maximum daily dose: 80 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27504360','lexi-content-ref-17156708','lexi-content-ref-338390','lexi-content-ref-17044900','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27504360','lexi-content-ref-17156708','lexi-content-ref-338390','lexi-content-ref-17044900','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Lower initial doses (5 to 10 mg/day) have also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-338390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-338390'])">Ref</a></span>). Higher maximum daily doses (up to 200 mg/<b>day</b>) have been described in some patients in a retrospective review; usually the higher doses were needed over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17156708']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17156708'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intrathecal:</i>
<b>Note:</b> Dosage adjustments may be required often during the first few months of therapy to adjust for lifestyle changes due to alleviation of spasticity. Maintain lowest dose that produces adequate response. Most patients require gradual increases over time to maintain optimal response. Sudden large requirements for a dose increase may indicate a catheter complication (eg, kink, dislodgement). Titrate dose to allow sufficient muscle tone and occasional spasms to optimize activities of daily living, support circulation, and possibly prevent deep vein thrombosis (DVT) formation. <b>Use extreme caution when filling the pump; follow manufacturer instructions carefully.</b> With chronic therapy, 5% to 10% of patients will become refractory to dose adjustments; may consider a drug holiday (hospitalized patients only) with a gradual withdrawal over 2 to 4 weeks and use of alternative spasticity management methods. Following the drug holiday, intrathecal baclofen may be resumed at the initial continuous infusion dose. Limited data available in children &lt;4 years; dosing for this age group based on expert consensus recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25188830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25188830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Screening dose: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;4 years: Limited data available: Intrathecal: Initial: 25 <b>mcg</b>; if response is inadequate, double the initial dose and administer 24 hours after the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25188830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25188830'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥4 years and Adolescents: Intrathecal: Initial: 50 <b>mcg</b> (1 mL) for 1 dose; for patients considered very small for age, a 25 <b>mcg</b> initial screening dose may be considered; following administration of screening dose, observe patient for 4 to 8 hours. A positive response consists of a significant decrease in muscle tone and/or frequency and/or severity of spasms. If response is inadequate, may increase screening dose in 25 <b>mcg</b> increments every 24 hours until a 4- to 8-hour positive clinical response is demonstrated or 100 <b>mcg</b>/dose is given. Patients not responding to screening dose of 100 <b>mcg</b> should not be considered for chronic infusion/implanted pump (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dose titration following pump implant:</i> Children and Adolescents: After positive response to screening dose, a maintenance intrathecal infusion can be administered via an implanted intrathecal pump.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial total daily dose via pump: Children and Adolescents: Intrathecal: Double the screening dose that gave a positive response and administer over 24 hours, unless efficacy of the bolus dose was maintained for &gt;8 hours or if negative reactions to the screening test dose (change in mental status, loss of function, or change in vital signs) occurred, then infuse a dose equivalent to the screening dose over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27433993','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27433993','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Do not increase dose in first 24 hours (to allow steady state to be achieved); thereafter, increase daily dose slowly by 5% to 15% once every 24 hours until satisfactory response is achieved; usual range: 50 to 100 <b>mcg</b> daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25188830','lexi-content-ref-27433993','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25188830','lexi-content-ref-27433993','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose titration </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25188830','lexi-content-ref-27433993','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25188830','lexi-content-ref-27433993','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents: Intrathecal:</p>
<p style="text-indent:-2em;margin-left:10em;">Inpatient titration: Daily dose may be increased periodically (eg, during pump refills) by 10% to 20% of dose; usual dose change is 50 <b>mcg</b>; maximum increment change: 100 <b>mcg</b>. <b>Note</b>: At lower doses, a 20% increase may be reasonable, but at higher doses a 20% increase may be excessive. Daily dose may be decreased by 10% to 20% for adverse effects.</p>
<p style="text-indent:-2em;margin-left:10em;">Outpatient titration: Daily dose may be increased periodically (eg, during pump refills) by 5% to 10% of daily dose (usual dose change is 25 <b>mcg</b>). Daily dose may be decreased by 10% to 20% for adverse effects.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Usual maintenance dose:</i> Children and Adolescents: Intrathecal: 100 to 2,000 <b>mcg</b> daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25188830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25188830'])">Ref</a></span>); the manufacturer provides the following:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 4 to 12 years: Intrathecal: 24 to 1,199 <b>mcg</b> daily (average: 274 <b>mcg</b>/day).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Intrathecal: 90 to 703 <b>mcg</b> daily; daily doses have ranged from 22 to 1,400 <b>mcg</b>; experience with doses &gt;1,000 <b>mcg</b> daily is limited.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073380"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, baclofen is primarily renally eliminated; use with caution; dosage reduction may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal: Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, baclofen is primarily renally eliminated; use with caution; dosage reduction may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51073381"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral, Intrathecal: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F138901"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9062" href="/d/html/9062.html" rel="external">see "Baclofen: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> A gradual dose taper (eg, over ≥1 to 2 weeks) is advised unless discontinuation is due to significant adverse effects or overdose-related emergencies; if withdrawal symptoms occur during discontinuation of chronic oral baclofen therapy, decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CSM.1997','lexi-content-ref-11597980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CSM.1997','lexi-content-ref-11597980'])">Ref</a></span>). Abrupt discontinuation of oral or intrathecal baclofen may result in severe adverse effects, including multiple organ-system failure and death.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="537d7c90-6631-4ce0-b2a7-9d4ee947be4f">Hiccups</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hiccups (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg 3 times daily; may increase dose based on response and tolerability; usual maximum dose: 45 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11917982','lexi-content-ref-7758557','lexi-content-ref-25052238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11917982','lexi-content-ref-7758557','lexi-content-ref-25052238'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="064c5452-fb88-4f4e-9599-745fd4b6f2cc">Muscle spasm and/or musculoskeletal pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Muscle spasm and/or musculoskeletal pain (adjunctive therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For skeletal muscle spasm and/or pain (eg, low back pain, neck pain) with muscle spasm, usually in combination with a nonsteroidal anti-inflammatory drug and/or acetaminophen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28192790','lexi-content-ref-12973146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28192790','lexi-content-ref-12973146'])">Ref</a></span>). In general, muscle relaxants should be used temporarily (eg, for a few days or intermittently for a few days when needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.2016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg 3 times daily as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Isaac.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Isaac.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9696f64-895f-4d97-bbb7-9feeb1ed243d">Spasticity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spasticity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Granules: Initial: 5 mg 3 times daily; may increase by 5 mg per dose every 3 days based on response and tolerability; maximum dose: 80 mg per day (20 mg 4 times per day).</p>
<p style="text-indent:-2em;margin-left:6em;">Solution, tablet: Initial: 5 mg 1 to 3 times daily; may increase by 5 mg per dose every 3 days based on response and tolerability; usual maximum dose: 80 mg/day in divided doses. Some patients may require doses up to 120 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Galvez-Jimenez.2020','lexi-content-ref-Olek.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Galvez-Jimenez.2020','lexi-content-ref-Olek.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Suspension: Initial: 5 mg (1 mL) 3 times daily; may increase by 5 mg (1 mL) per dose every 3 days based on response and tolerability; usual maximum dose: 80 mg (16 mL) per day (20 mg [4 mL] 4 times per day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intrathecal:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use extreme caution when filling the pump; follow manufacturer instructions.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Screening dose:</i> Initial bolus: 50 mcg over ≥1 minute then observe patient for 4 to 8 hours. A positive response consists of a significant decrease in muscle tone, frequency, and/or severity of spasms. If response is inadequate, may give 75 mcg as a second screening dose 24 hours after the first dose; observe patient for 4 to 8 hours. If response is still inadequate, may administer 100 mcg as a final screening dose 24 hours after the second dose. Patients not responding to screening dose of 100 mcg should not be considered for chronic infusion via implanted pump.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial total daily continuous infusion dose via implanted pump:</i></p>
<p style="text-indent:-2em;margin-left:8em;">If screening dose provided positive response for &gt;4 hours but &lt;8 hours: Double the screening dose that gave a positive response and administer over 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">If screening dose provided positive response for &gt;8 hours: Infuse a dose equivalent to the screening dose over 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial titration after pump implantation: Do not increase dose in first 24 hours to allow steady state to be achieved; thereafter, initial dosage adjustments may be made by increasing daily dose by 10% to 30% (spasticity of spinal cord origin) or by 5% to 15% (spasticity of cerebral origin) once every 24 hours until satisfactory response.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose and titration:</i> Daily dose may be increased periodically (eg, during pump refills) by 10% to 40% (maximum increase: 40%) for spasticity of spinal cord origin or by 5% to 20% (maximum increase: 20%) for spasticity of cerebral origin. Dose may also be decreased 10% to 20% for adverse effects. Most patients have been adequately maintained on 300 to 800 mcg daily (spasticity of spinal cord origin) or 90 to 703 mcg daily (spasticity of cerebral origin). Experience with doses &gt;1,000 mcg daily is limited.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990766"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">The following dosage adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24414993','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24414993','lexi-content-ref-Expert.DOR'])">Ref</a></span>): <b>Note:</b> Kidney function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;80 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 50 to 80 mL/minute: Initial: 5 mg every 12 hours; titrate cautiously to effect; do not exceed 50 mg/day or ~66% of the usual maximum daily dose, whichever is less.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to &lt;50 mL/minute: Initial: 2.5 mg every 8 hours; titrate cautiously to effect; do not exceed 40 mg/day or ~50% of the usual maximum daily dose, whichever is less.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: Avoid use; in some patients, even low initial doses for short duration have led to toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22041434','lexi-content-ref-12769509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22041434','lexi-content-ref-12769509'])">Ref</a></span>). If baclofen use cannot be avoided, initiate at a low dose (eg, 2.5 mg every 12 hours or less); titrate with extreme caution to effect; do not exceed 20 mg/day or ~33% of the usual maximum daily dose, whichever is less.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intrathecal:</b> Mild to severe impairment: There are no specific dosage adjustments recommended. However, baclofen is primarily eliminated by the kidney; use with caution; dosage reduction may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Dialyzable (1 case report of 79% removal with a 4-hour session) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15615812']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15615812'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, intrathecal:</b> Avoid use. Numerous case reports and 1 population-based cohort study have demonstrated significant adverse events related to chronic maintenance dosing and unintentional overdoses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450156','lexi-content-ref-9391686','lexi-content-ref-22041434','lexi-content-ref-11684810','lexi-content-ref-30537935','lexi-content-ref-23682655','lexi-content-ref-31384209','lexi-content-ref-27789113','lexi-content-ref-20044395','lexi-content-ref-28899601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450156','lexi-content-ref-9391686','lexi-content-ref-22041434','lexi-content-ref-11684810','lexi-content-ref-30537935','lexi-content-ref-23682655','lexi-content-ref-31384209','lexi-content-ref-27789113','lexi-content-ref-20044395','lexi-content-ref-28899601'])">Ref</a></span>). If baclofen use cannot be avoided, initiate at a low dose (eg, 2.5 mg orally every 12 hours or less); titrate with extreme caution to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450156'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, intrathecal:</b> Avoid use. Baclofen clearance by peritoneal dialysis has not been characterized. Multiple case reports have reported hospitalization for encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12739836','lexi-content-ref-23682655','lexi-content-ref-17091060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12739836','lexi-content-ref-23682655','lexi-content-ref-17091060'])">Ref</a></span>). If baclofen use cannot be avoided, initiate at a low dose (eg, 2.5 mg orally every 12 hours or less); titrate with extreme caution to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450156'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, intrathecal:</b> Avoid use. If baclofen use cannot be avoided, initiate at a low dose; titrate cautiously to effect (expert opinion). <b>Note:</b> CRRT data are primarily limited to the treatment of acute baclofen intoxication, which have demonstrated significant increases in baclofen clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25567218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25567218'])">Ref</a></span>). However, because CRRT is often used short term and in acutely ill patients, dose increases in response to increased clearance are not recommended unless clinically indicated (eg, increased spasticity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, intrathecal:</b> Avoid use. Pharmacokinetics of baclofen in patients receiving PIRRT have not been well characterized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987870"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral and intrathecal: There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block arsc drugH1Div" id="F54861285"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">CNS effects may include <b>confusion</b>, <b>dizziness</b>,<b> drowsiness, </b>sedation, <b>asthenia</b>, <b>nausea, </b>and<b> vomiting</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18578471','lexi-content-ref-23074476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18578471','lexi-content-ref-23074476'])">Ref</a></span>). CNS effects may impair physical or mental abilities and be additive to alcohol and other CNS depressants (eg, opioids, benzodiazepines). Multiple cases describing neurotoxicity due to oral baclofen accumulation in adult patients with varying levels of renal impairment have been reported in the literature. In one study of 6,469 older adults on dialysis (360 receiving baclofen), 7.2% of patients started on baclofen were hospitalized for encephalopathy (median time to hospitalization of 3 days) compared to &lt;0.1% of patients not receiving baclofen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450156'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Reduces the release of excitatory neurotransmitters by binding to the GABA-B presynaptic receptors within the brain stem, dorsal horn of the spinal cord, and other CNS sites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23074476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23074476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Oral doses &gt;60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15350152','lexi-content-ref-23074476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15350152','lexi-content-ref-23074476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Oral (vs intrathecal) administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15350152','lexi-content-ref-23074476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15350152','lexi-content-ref-23074476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Severe kidney dysfunction (eGFR &lt;30 mL/minute/1.73m<sup>2</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32450156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32450156'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Intrathecal baclofen: Abrupt withdrawal of intrathecal baclofen has been associated with altered mental status, exaggerated rebound spasticity, high <b>fever</b>, and <b>muscle rigidity</b> (which in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12382179','lexi-content-ref-12645974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12382179','lexi-content-ref-12645974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral baclofen: Abrupt withdrawal of oral baclofen has been associated with altered mental status, exaggerated rebound spasticity, <b>hallucination</b>, high <b>fever</b>, <b>hypertension</b>, hyperthermia, muscle rigidity, tachycardia, and <b>seizure</b>. Other symptoms include<b> agitation</b>, <b>confusion</b>, delusions, <b>insomnia</b>, and <b>paranoid ideation</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28042369','lexi-content-ref-1443727','lexi-content-ref-3731773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28042369','lexi-content-ref-1443727','lexi-content-ref-3731773'])">Ref</a></span>). <b>Neonatal withdrawal</b> has also been reported in neonates whose mothers were treated with oral baclofen throughout pregnancy (Ratnayaka 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Withdrawal; related to the release of excitatory neurotransmitters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15350152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15350152'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; symptoms appear within hours to a few days following interruption of intrathecal therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15301690','lexi-content-ref-27434299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15301690','lexi-content-ref-27434299'])">Ref</a></span>) and within 12 to 72 hours after discontinuation of oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1443727','lexi-content-ref-3731773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1443727','lexi-content-ref-3731773'])">Ref</a></span>). Neonatal withdrawal has been reported within hours to days after delivery.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Pump malfunction or removal (eg, battery failure, catheter displacement, infection, intrathecal mass) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10340425','lexi-content-ref-15350152','lexi-content-ref-15301690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10340425','lexi-content-ref-15350152','lexi-content-ref-15301690'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preventable human errors (eg, programming or pump refill errors, oral baclofen administration or refill errors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10340425','lexi-content-ref-28042369','lexi-content-ref-15301690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10340425','lexi-content-ref-28042369','lexi-content-ref-15301690'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with spinal cord injuries at T-6 or above, communication difficulties, or history of withdrawal symptoms from intrathecal or oral baclofen</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F138868"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤12%), vomiting (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤15%), confusion (≤11%), dizziness (2% to 15%), drowsiness (≤63%), headache (2% to 11%), hypotonia (2% to 35%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≤9%), peripheral edema (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (4%), urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (≤6%), diarrhea (≤2%), sialorrhea (3%), xerostomia (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Difficulty in micturition (2%), impotence (≤2%), urinary frequency (≤6%), urinary incontinence (≤2%), urinary retention (≤8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (≤1%), agitation (≤1%), chills (≤1%), coma (≤2%), depression (2%), fatigue (2% to 4%), insomnia (≤7%), pain (≤4%), paresthesia (≤7%), seizure (≤10%), speech disturbance (≤4%), tremor (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≤1%), hypoventilation (≤4%), pneumonia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (≤4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ankle edema (Bence 2014), bradycardia (Rifici 2011; Sechrist 2015), chest pain, hypertension, palpitations, syncope, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, contact dermatitis, dermal ulcer, hyperhidrosis, skin rash (Pathak 2019; Saddichha 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (Hemingway 2001; Yang 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (Chen 1997), anorexia, dysgeusia, dysphagia, fecal incontinence, gastrointestinal hemorrhage, occult blood in stools, tongue irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, hematuria, inhibited ejaculation (Saval 2008), nocturia, oliguria, vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Carcinoma, leukocytosis (Gee 2016), petechial rash</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia (Karol 2011), amnesia (Grande 2008; Zeman 2016), anxiety, ataxia (Porter 2017), dysarthria, dysautonomia, dystonia, euphoria (Das 2016; Ghosh 2017), excitement, hallucination, hyporeflexia, hypothermia (Singh 2009), hysteria, malaise, opisthotonus, personality disorder, slurred speech</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle rigidity, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, blurred vision, diplopia, miosis, mydriasis, nystagmus disorder, strabismus</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (Auffret 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea (Locatelli 2019; Olivier 2016), hyperventilation, nasal congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (can be high fever with drug withdrawal)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum glucose</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombophlebitis (Carda 2008), pulmonary embolism (Carda 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (Hornyak 2005), weight loss (Arima 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Intestinal obstruction (Karthikeyan 2015), paralytic ileus (Morant 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (Denys 1998), orgasm disturbance (Hornyak 2005; Saval 2008), priapism, sexual disorder (McGehee 2006; Saval 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium (Chauvin 2020), disorientation (Chauvin 2020), neonatal withdrawal (Ratnayaka 2001), suicidal ideation (Pelissier 2017; WeiBhaar 2012), transient ischemic attacks (Chauvin 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Scoliosis (Panagopoulos 2020), scoliosis progression (Ginsburg 2007; Walker 2017)</p></div>
<div class="block coi drugH1Div" id="F138882"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to baclofen or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal formulation: IV, IM, SubQ, or epidural administration</p></div>
<div class="block war drugH1Div" id="F138865"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Intrathecal mass: Cases (most from pharmacy compounded preparations) of intrathecal mass formation at the implanted catheter tip have been reported; patients may experience worsening or return of spasticity, pain, inadequate response to dose adjustments, and/or neurological deficit/dysfunction. Neurosurgical evaluation and/or an appropriate imaging study should be considered if a mass is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention: May cause acute urinary retention (may be related to underlying disease); use with caution in patients with urinary obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Autonomic dysreflexia: Use with caution in patients with a history of autonomic dysreflexia; presence of nociceptive stimuli or abrupt baclofen withdrawal may cause an autonomic dysreflexic episode.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disorders: Use with caution in patients with peptic ulcer disease, decreased GI motility, and/or GI obstructive disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disease: Use with caution in patients with psychotic disorders, schizophrenia, or confusional states; may cause exacerbation of condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; baclofen is eliminated primarily unchanged via the kidneys.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with respiratory disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Loss of seizure control has been reported in patients treated with baclofen; use with caution and monitor patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients; may be more sensitive to adverse CNS effects, especially at higher doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Neonatal withdrawal symptoms (eg, increased muscle tone, jitteriness, tremor, seizure), beginning hours to days after delivery, have been reported in neonates born to mothers treated with baclofen throughout pregnancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Intrathecal: Children should be of sufficient body mass to accommodate the implantable pump for chronic infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Oral products: Multiple products available; ensure appropriate strength and dose of the oral formulation prior to administering, dispensing, and prescribing; oral <b>suspension</b> is a concentrated formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Intrathecal: For use only in an FDA-approved implantable pump for intrathecal baclofen administration; health care providers should be experienced with chronic intrathecal infusion therapy and resuscitative equipment should be readily available. Ensure patient is infection-free and then evaluate patient's response to bolus intrathecal injection (screening phase) prior to implanting pump. Monitor closely during the initial phase of pump use and when adjusting the dosing rate and/or the concentration in the reservoir. Educate patients and caregivers on proper home care of the pump and insertion site. Use extreme caution when filling an implantable pump; pumps should only be refilled through the reservoir refill septum. Inadvertent injection into the subcutaneous tissue can occur if the reservoir refill septum is not properly accessed. Some pumps are equipped with a catheter access port that allows direct access to the intrathecal catheter; direct injection into this catheter access port or inadvertent injection into the subcutaneous tissue may cause a life-threatening overdose. Except in overdose related emergencies, intrathecal baclofen should be reduced slowly if discontinuation is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Oral: Efficacy of oral baclofen has not been established in patients with Parkinson disease or cerebral palsy; therefore, use is not recommended. Use caution in patients with a history of stroke; poor tolerability to baclofen without significant benefit has been observed. Not indicated for spasticity associated with rheumatic disorders. Use with caution when spasticity is utilized to sustain upright posture and balance in locomotion, or when spasticity is necessary to obtain increased function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Overdose: Intrathecal use: Monitor closely for signs and symptoms of overdose, which may appear suddenly or insidiously, especially during the initial screening and dose-titration phase of treatment, and during reintroduction of therapy after a period of interruption. Signs/symptoms of overdose may include drowsiness, dizziness, somnolence, hypothermia, respiratory depression, seizures, rostral progression of hypotonia, and loss of consciousness progressing to coma. If overdose is suspected, patient should be evaluated immediately in a hospital setting and the pump reservoir emptied.</p></div>
<div class="block dosfc drugH1Div" id="F23884414"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;margin-left:0em;display:inline">First-Baclofen suspension is a compounding kit. Refer to manufacturer’s labeling for compounding instructions.</p></div>
<div class="block foc drugH1Div" id="F138875"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyvispah: 5 mg (90 ea [DSC]) [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyvispah: 5 mg (90 ea) [contains saccharin sodium; strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyvispah: 10 mg (90 ea [DSC]) [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyvispah: 10 mg (90 ea) [contains saccharin sodium; strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyvispah: 20 mg (90 ea [DSC]) [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyvispah: 20 mg (90 ea) [contains saccharin sodium; strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lioresal: 0.05 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lioresal: 10 mg/20 mL (20 mL); 10 mg/5 mL (5 mL); 40 mg/20 mL (20 mL) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/20 mL (20 mL); 40 mg/20 mL (20 mL); 20,000 mcg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gablofen: 10,000 mcg/20 mL (20 mL); 20,000 mcg/20 mL (20 mL) [antioxidant free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gablofen: 40,000 mcg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lioresal: 0.05 mg/mL (1 mL); 40 mg/20 mL (20 mL) [antioxidant free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lioresal: 10 mg/20 mL (20 mL); 10 mg/5 mL (5 mL) [antioxidant free, pyrogen free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/20 mL (20 mL); 40 mg/20 mL (20 mL); 20,000 mcg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ozobax: 5 mg/5 mL (473 mL [DSC]) [contains methylparaben, propylparaben; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ozobax DS: 10 mg/5 mL (237 mL, 473 mL) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (473 mL); 10 mg/5 mL (237 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intrathecal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gablofen: 50 mcg/mL (1 mL) [antioxidant free, latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gablofen: 20,000 mcg/20 mL (20 mL) [antioxidant free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gablofen: 10,000 mcg/20 mL (20 mL); 40,000 mcg/20 mL (20 mL) [antioxidant free, pyrogen free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fleqsuvy: 25 mg/5 mL (120 mL, 300 mL) [contains fd&amp;c red #40 (allura red ac dye), propylene glycol, quinoline yellow (d&amp;c yellow #10), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/5 mL (120 mL, 250 mL, 300 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F138861"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F138884"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Lyvispah Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $3.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $3.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $3.93</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Baclofen Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/20 mL (per mL): $7.08 - $11.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/20 mL (per mL): $28.38 - $46.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Baclofen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $1.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $3.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gablofen Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 mcg/20 mL (per mL): $14.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 mcg/20 mL (per mL): $28.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40000 mcg/20 mL (per mL): $56.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lioresal Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/mL (per mL): $39.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/20 mL (per mL): $14.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $56.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/20 mL (per mL): $56.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ozobax DS Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $4.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Baclofen Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/mL (per mL): $52.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Gablofen Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/mL (per mL): $105.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 mcg/20 mL (per mL): $15.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 mcg/20 mL (per mL): $30.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40000 mcg/20 mL (per mL): $61.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Baclofen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $6.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Fleqsuvy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $7.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Baclofen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.34 - $1.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.14 - $2.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.16 - $5.13</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866029"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lioresal Intrathecal: 500 mcg/mL ([DSC]); 2000 mcg/mL ([DSC]); 0.05 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mcg/mL (20 mL); 0.05 mg/mL (1 mL); 2 mg/mL (5 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lioresal: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lioresal DS: 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p></div>
<div class="block exp drugH1Div" id="F138880"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Baclofen is commercially available as 1 mg/mL or 5 mg/mL oral suspension (First-Baclofen compounding kit [1 mg/mL or 5 mg/mL]; Fleqsurvy 5 mg/mL) or as a 1 mg/mL oral solution (Ozobax). Compounded oral suspension may be available in multiple concentrations (eg, up to 10 times more concentrated); use caution to avoid confusion; verify concentration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>5 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 5 mg/mL oral suspension may be made with tablets. Crush thirty 20 mg tablets in a mortar and reduce to a fine powder. Add a small amount of glycerin and mix to a uniform paste. Mix while adding Simple Syrup, NF in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add a sufficient quantity of vehicle to make 120 mL. Label “shake well” and “refrigerate.” Stable for 35 days (Johnson 1993).</p>
<div class="reference">Johnson CE, Hart SM. Stability of an extemporaneously compounded baclofen oral liquid. <i>Am J Hosp Pharm.</i> 1993;50(11):2353-2355.<span class="pubmed-id">8266961</span></div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>10 mg/mL</b>
<b>Oral Suspension: Note: </b>Commercially available suspension is more dilute (eg, up to 10 times more dilute); use caution to avoid confusion; verify concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">A 10 mg/mL oral suspension may be made with tablets. Crush one-hundred-twenty 10 mg tablets in a mortar and reduce to a fine powder. Add small portions (60 mL) of a 1:1 mixture of Ora-Sweet and Ora-Plus and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label “shake well” and “refrigerate.” Stable for 60 days (Allen 1996).</p>
<div class="reference">Allen LV Jr, Erickson MA 3rd. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm.</i> 1996;53(18):2179-2184.<span class="pubmed-id">8879325</span></div>
</div>
<div class="block admp drugH1Div" id="F52612282"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals. If nausea occurs, may administer with food or milk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-LioresalTablets.2020.05']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-LioresalTablets.2020.05'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral liquid: Baclofen is available as both an oral solution and oral suspension; concentration varies by product; use extra caution during product selection and preparation and verify correct product/concentration is chosen. When using oral liquid product, administer with a calibrated measuring device; do not use a household teaspoon (overdosage may occur).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oral suspension: </i>Shake well prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral granules: Contents of packet may be emptied into the mouth and swallowed or may be mixed with up to 15 mL of liquid or soft food (eg, applesauce, yogurt, pudding). If mixing with food, entire mixture should be consumed within 2 hours of mixing. If multiple packets are needed to complete dose, each packet must be mixed with separate volume of liquid or food.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Administration via feeding tube:</i> Oral granules may be administered by NG tube ≥8 French, gastrostomy tubes (G tube) ≥12 French, percutaneous endoscopic gastrostomy (PEG) tube ≥14 French, or gastrojejunostomy (GJ) tube ≥16 French. Prior to administration, flush feeding tube with up to 15 mL of water using a catheter tip syringe. Empty contents of 1 packet into 15 mL of liquid (eg apple juice or milk) and mix until granules wetted. Draw up suspension of granules/liquid into dosing syringe and administer via feeding tube. Using same syringe, flush the feeding tube with 15 mL of water after administration. Repeat process if multiple packets are needed to complete a dose. If dosing syringe is allowed to stand for ≥15 minutes prior to administration, invert syringe 3 times to ensure baclofen is mixed; administration must be completed within 2 hours of initial mixing.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Intrathecal: Screening dosage: Administer as a bolus injection by barbotage into the subarachnoid space over at least 1 minute, followed by maintenance infusion via implantable infusion pump; do not abruptly discontinue intrathecal baclofen administration. Do not administer intrathecal formulation IV, IM, SUBQ, or epidurally.</p></div>
<div class="block adm drugH1Div" id="F138878"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrathecal:</b> For screening dosages, administer as a bolus injection (50 mcg/mL concentration) by barbotage into the subarachnoid space over at least 1 minute, followed by maintenance continuous infusion. Do not administer intrathecal formulation IV, IM, SUBQ, or epidurally.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Granules: Contents of packet may be emptied into the mouth and swallowed or may be mixed with up to 15 mL of liquid or soft food (eg, applesauce, yogurt, pudding). If mixing with food, entire mixture should be consumed within 2 hours of mixing. If multiple packets are needed to complete dose, each packet must be mixed with separate volume of liquid or food.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution, suspension: Administer without regards to meals. Shake suspension well; use a calibrated measuring device to administer; do not use a household teaspoon or tablespoon.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Feeding tube:</b> Oral granules may be administered by NG tube ≥8 French, gastrostomy tubes (G tube) ≥12 French, percutaneous endoscopic gastrostomy (PEG) tube ≥14 French, or gastrojejunostomy (GJ) tube ≥16 French. Prior to administration, flush feeding tube with up to 15 mL of water using a catheter tip syringe. Empty contents of 1 packet into 15 mL of liquid (eg, apple juice, milk) and mix until granules are wetted. Draw up suspension of granules/liquid into dosing syringe and administer via feeding tube. Using same syringe, flush the feeding tube with 15 mL of water after administration. Repeat process if multiple packets are needed to complete a dose. If dosing syringe is allowed to stand for ≥15 minutes prior to administration, invert syringe 3 times to ensure baclofen is mixed; administration must be completed within 2 hours of initial mixing.</p></div>
<div class="block sts drugH1Div" id="F26641826"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Do not store above 30°C (86°F). Does not require refrigeration. Do not freeze or heat sterilize. Discard any unused solution.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral granules: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution:</p>
<p style="text-indent:-2em;margin-left:4em;">Ozobax: Store refrigerated at 2°C to 8°C (36°F to 46°F). Dispense in a light-resistant container.</p>
<p style="text-indent:-2em;margin-left:4em;">Ozobax DS: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Dispense in a light-resistant container.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Store at 20°C to 25°C (68°F to 77°F); excursion permitted between 15°C to 30°C (59°F to 86°F). Discard any unused portion 2 months after first opening.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53565584"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Tablets, granules (eg, Lyvispah), solution (eg, Ozobax), suspension (eg, Fleqsuvy): Management of reversible spasticity associated with multiple sclerosis or spinal cord lesions (FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal: Management of severe spasticity of spinal cord origin (eg, spinal cord injury, multiple sclerosis) or cerebral origin (eg, cerebral palsy, traumatic brain injury); may also be considered as an alternative to destructive neurosurgical procedures (Gablofen, Lioresal: FDA approved in ages ≥4 years and adults). <b>Note:</b> Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long-term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy.</p></div>
<div class="block mst drugH1Div" id="F138951"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Baclofen may be confused with Bactroban</p>
<p style="text-indent:-2em;margin-left:4em;">Lioresal may be confused with lisinopril, Lotensin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Different concentrations of the oral liquid are available; ensure appropriate strength and dose of oral liquid prior to administering, dispensing, and prescribing.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298810"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F138870"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: Muscle Relaxants (Centrally Acting) may enhance the adverse/toxic effect of Botulinum Toxin-Containing Products. Specifically, the risk for increased muscle weakness may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: Baclofen may enhance the hypotensive effect of Lacidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolperisone: May enhance the adverse/toxic effect of Muscle Relaxants (Centrally Acting). Management: Monitor for increased sedation or CNS effects if tolperisone is combined with other centrally acting muscle relaxants. Consider decreasing the tolperisone dose if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Baclofen may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F13273272"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Late-onset neonatal withdrawal may occur following in utero exposure. Feeding difficulties, high-pitched cry, hyperthermia, hypertonicity, loose stools, tremors, and seizures have been reported in newborns following maternal use of oral baclofen throughout pregnancy (Duncan 2013; Freeman 2016; Ratnayaka 2001). Use of intrathecal baclofen in pregnant females has been described (Dalton 2008; Hara 2018; Méndez-Lucena 2016; Tandon 2010). Maternal plasma concentrations following administration of intrathecal baclofen are significantly less than those with oral doses; exposure to the fetus is expected to be limited and adverse neonatal events have not been noted in available reports (Morton 2009).</p></div>
<div class="block mopp drugH1Div" id="F53565586"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs and symptoms of baclofen withdrawal (eg, altered mental status, exaggerated rebound spasticity, hallucinations, high fever, hypertension, hyperthermia, muscle rigidity, tachycardia, seizure, agitation, confusion, delusions, insomnia, paranoid ideation). Consider EEG in patients with epilepsy if clinically indicated (decreased seizure threshold has been reported). Monitor closely for signs and symptoms of overdose (eg, drowsiness, dizziness, somnolence, hypothermia, respiratory depression, seizures, rostral progression of hypotonia, loss of consciousness progressing to coma), which may appear suddenly or insidiously, especially during the initial screening and dose-titration phase of treatment, and during reintroduction of therapy after a period of interruption.</p></div>
<div class="block pha drugH1Div" id="F138864"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits the transmission of both monosynaptic and polysynaptic reflexes at the spinal cord level, possibly by hyperpolarization of primary afferent fiber terminals, with resultant relief of muscle spasticity</p></div>
<div class="block phk drugH1Div" id="F138881"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Intrathecal bolus: 30 minutes to 1 hour; Continuous infusion: 6 to 8 hours after infusion initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Intrathecal bolus: 4 hours (effects may last 4 to 8 hours); Continuous infusion: 24 to 48 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption (dose dependent): Oral: Rapid; absorption from the GI tract is thought to be dose dependent; in pediatric patients (age range: 2 to 17 years) with cerebral palsy, absorption from GI tract highly variable and delayed (reported time lag: 0.59 ± 0.28 hours) (He 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 74% (Agarwal 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 30%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Volume of distribution: Pediatric patients (age range: 2 to 17 years: Oral: Highly variable: 1.16 L/kg with 43.5% interindividual variability (He 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (15% of dose) (He 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients with cerebral palsy (age range: 2 to 17 years): 4.5 hours (He 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Granules: 5.5 hours; Solution: ~5.7 hours; Suspension: ~5.6 hours; Tablets: 3.75 ± 0.96 hours (Brunton 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Intrathecal: CSF elimination half-life: 1.51 hours over the first 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 1 hour (0.5 to 4 hours) (Brunton 2011); Solution: 0.75 hours; Suspension: 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;70% as unchanged drug) and feces (Brunton 2011).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038536"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Baclodox | Baclofeno Cevallos | Baclox | Bafen | Flimab | Lioresal | Lioresal intratecal | Roclofeno</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Baclofen meduna | Baclofen sintetica | Lioresal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-baclofen | Baclo | Baclohexal | Bacthecal | Clofen | Cm baclofen | Dbl baclofen | Lioresal | Sintetica baclofen intrathecal | Stelax | Tw baclofen</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Bacaid | Bacben | Bacifen | Backtone | Baclobac | Bacloflex | Baclon | Bacmax | Bacofen | Bactab | Beclo | Beclovan | Beklo | C Bac | Easybak | Fenobac | Flexibac | Flexifen | Flexilax | Liofen | Liorel | Lioresal | Liosal | Lirosal | Lospan | Maxolax | Muslofen | Mylofen | Myobac | Myorel | Reflexen | Relofen | Rembac | Restobac | Skelofen | Smr | Spafen | Spaflex | Spakem | Spinafen | Spinofen | Starbac | Xanbac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Baclofen Aguettant | Baclofen merck-generics | Lioresal | Lioresal intrathec | Spacyr</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Baclofen pharmadvice</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Baclofeno | Baclon | Lioresal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Baclocalm | Baclofen intrathecal sintetica | Baclofen sintetica | Lioresal</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Baclofeno | Cetril | Lioresyl</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lioresal | Shu fen | Spinax | Zufen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Baclosan | Balanfen | Balyria | Distentia | Lioresal | Spastifen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Baclofen meduna</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Baclaxiro | Baclofen AL | Baclofen dura | Baclofen meduna | Baclofen neuraxpharm | Baclofen sintetica | Baclofen Sun | Gablofen | Lebic | Lioresal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Diafen | Lioresal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Baclofen meduna | Baclofen sintetica | Baclophen | Baclosal | Lioresal | Lioresal intrathecal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lioresal | Mylobac</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Baclofen Merck NM | Baclofen sintetica | Baclon | Baclopar | Baklofen mylan | Lioresal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Baclocur | Baclofene aguettant | Baclofene eg | Baclofene irex | Baclofene sun | Lioresal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Baclofen almus | Baclofen arrow | Baclofen berk | Baclofen cox | Baclofen Focus | Baclofen kent | Baclofen sandoz | Baclofen Teva | Baclospas | Balgifen | Gablofen | Lioresal | Lyflex | Relamex | Trav baclofen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Miorel | Vioridon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-baclofen | Apt Baclofen | Lioresal | Pms baclofen | Qualisal</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Baclopar | Lioresal</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Baclosal | Lioresal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bacfen | Bacfen xl | Baclesta | Baclocare | Baclof | Bacloren | Baclorest | Baclosol | Baclosure | Baclosure xl | Baclotab | Baclotop | Bolofen | Chinofen | Fenbac xr | Gleefen | Liofen | Lioresal | Spinospas | Tefsole</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Baclofene bioindustria | Baclofene doc | Baclofene Mylan | Lioresal</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Baclocalm | Lioresal</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gabalon | Lioresal | Siobarofen | Torobamin | Torobamin choseido</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Balcon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Baclafon | Baclan | Baclen | Baclfen | Baclon | Bacron | Baken | Bancloven | Barapa | Baront | Baropan | Baropen | Bigafen | Chinofen | Curofen | Daewoo baclofen | Dapro | Dongkoo baclofen | Gl baclofen | Handok baclofen | Hawon baclofen | Lioresal | Newgenpharm baclofen | Prex | Prinda | Rexfen | Samsung baclofen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lioresal | Lioresal intrathec</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Baclofen ratiopharm | Baclosal | Lioresal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Mylinax</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Baclofen sintetica | Clofen | Liobac | Lioresal | Musafen | Pms baclofen</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Baclofen bp</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Baclofen Actavis | Baclofen sintetica | Baclofen Teva | Gablofen | Lioresal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Baclofen intrathecal | Baclofen nmd grossist | Baclofen sintetica | Baklofen | Lionova | Lioresal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Alpha-baclofen | Lioresal | Pacifen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Baclodrint | Baclofeno | Espast</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Baclo | Lioresal | Liosal | Onelaxant R | Trilaxant</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aerofin | Bacfen | Bacgen | Baclast | Baclin | Bacmax | Baflex | Bakin | Beclotab | Biobec | Fexibil | Lioresal | Liorex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Baclofen sintetica | Lioresal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">First baclofen | Gablofen | Lioresal | Lioresal DS | Ozobax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Baclofeno | Baclofeno generis | Lioresal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Diafen | Lioresal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Baclocalm | Lioresal</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Baclasan | Baclosan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-baclofen | Colmifen | Lioresal | Pms baclofen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Baclofen medical valley | Baklofen 2care4 | Baklofen Alternova | Baklofen Bluefish | Baklofen Merck NM | Baklofen mylan | Gablofen | Lionova | Lioresal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-baclofen | Colmifen | Lioresal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Baclofen polpharma | Fezea | Lioresal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Baclosal | Bafen | Centrafen | Fenisal | Liobac | Lioresal | Musclofen | Myofen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Liorefen | Lioresal | Pms baclofen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lioresal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Baclon | Bacone | Bacton | Bafen | Balax | Befon | Colmifen | Gabalon | Gablofen | Legafen | Lioresal | Maclofen | Mulax | Muscofen | Pacifen | Pickton | Solofen | Spinax | Sugei</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Baclof | Baclopert | Diafen | Lioresal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bamifen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen baclofen | Bacentra intrathecal | Baclofen unichem | Lioresal | Norton-baclofen | Teva baclofen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25028414">
<a name="25028414"></a>Agarwal SK, Kriel RL, Cloyd JC, et al. A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers. <i>J Child Neurol</i>. 2015;30(1):37-41. doi:10.1177/0883073814535504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/25028414/pubmed" id="25028414" target="_blank">25028414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8291951">
<a name="8291951"></a>Aisen ML, Dietz M, McDowell F, Kutt H. Baclofen toxicity in a patient with subclinical renal insufficiency. <i>Arch Phys Med Rehabil</i>. 1994;75(1):109-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/8291951/pubmed" id="8291951" target="_blank">8291951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12382179">
<a name="12382179"></a>Alden TD, Lytle RA, Park TS, Noetzel MJ, Ojemann JG. Intrathecal baclofen withdrawal: a case report and review of the literature. <i>Childs Nerv Syst</i>. 2002;18(9-10):522-525. doi:10.1007/s00381-002-0634-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/12382179/pubmed" id="12382179" target="_blank">12382179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10340425">
<a name="10340425"></a>Al-Khodairy AT, Vuagnat H, Uebelhart D. Symptoms of recurrent intrathecal baclofen withdrawal resulting from drug delivery failure: a case report. <i>Am J Phys Med Rehabil</i>. 1999;78(3):272-277. doi:10.1097/00002060-199905000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/10340425/pubmed" id="10340425" target="_blank">10340425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18578471">
<a name="18578471"></a>Alstermark C, Amin K, Dinn SR, et al. Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors. <i>J Med Chem</i>. 2008;51(14):4315-4320. doi:10.1021/jm701425k<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/18578471/pubmed" id="18578471" target="_blank">18578471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28042369">
<a name="28042369"></a>Alvis BD, Sobey CM. Oral baclofen withdrawal resulting in progressive weakness and sedation requiring intensive care admission. <i>Neurohospitalist</i>. 2017;7(1):39-40. doi:10.1177/1941874416637404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/28042369/pubmed" id="28042369" target="_blank">28042369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.2016">
<a name="APS.2016"></a>American Pain Society (APS). <i>Principles of Analgesic Use.</i> 7th ed. American Pain Society; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20930428">
<a name="20930428"></a>Arima H, Oiso Y. Positive effect of baclofen on body weight reduction in obese subjects: a pilot study. <i>Intern Med</i>. 2010;49(19):2043-2047. doi:10.2169/internalmedicine.49.3918<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/20930428/pubmed" id="20930428" target="_blank">20930428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2017">
<a name="ASHP.2017"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24577148">
<a name="24577148"></a>Auffret M, Rolland B, Deheul S, et al; CAMTEA Team. Severe tinnitus induced by off-label baclofen. <i>Ann Pharmacother</i>. 2014;48(5):656-659. doi:10.1177/1060028014525594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/24577148/pubmed" id="24577148" target="_blank">24577148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baclofen.2019.12">
<a name="Baclofen.2019.12"></a>Baclofen tablet [prescribing information]. Memphis, TN: Northstar Rx LLC; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amneal.1">
<a name="Amneal.1"></a>Baclofen tablets [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Innogenix.1">
<a name="Innogenix.1"></a>Baclofen tablets [prescribing information]. Amityville, NJ: Innogenix LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24293402">
<a name="24293402"></a>Bence C, Cottencin O, Deheul S, Gautier S, Bordet R, Rolland B. Baclofen-induced edema in alcohol use disorders. <i>J Clin Pharmacol</i>. 2014 ;54(4):478-481. doi:10.1002/jcph.233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/24293402/pubmed" id="24293402" target="_blank">24293402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25188830">
<a name="25188830"></a>Berweck S, Lütjen S, Voss W, et al. Use of intrathecal baclofen in children and adolescents: interdisciplinary consensus table 2013. <i>Neuropediatrics</i>. 2014;45(5):294-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/25188830/pubmed" id="25188830" target="_blank">25188830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27433993">
<a name="27433993"></a>Boster AL, Adair RL, Gooch JL, et al. Best practices for intrathecal baclofen therapy: dosing and long-term management. <i>Neuromodulation</i>. 2016;19(6):623-631. doi:10.1111/ner.12388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/27433993/pubmed" id="27433993" target="_blank">27433993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11917982">
<a name="11917982"></a>Boz C, Velioglu S, Bulbul I, Ozmenoglu M. Baclofen is effective in intractable hiccups induced by brainstem lesions. <i>Neurol Sci</i>. 2001;22(5):409.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/11917982/pubmed" id="11917982" target="_blank">11917982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brunton.2011">
<a name="Brunton.2011"></a>Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. McGraw-Hill Medical; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18385632">
<a name="18385632"></a>Carda S, Cazzaniga M, Taiana C, Pozzi R. Intrathecal baclofen bolus complicated by deep vein thrombosis and pulmonary embolism. A case report. <i>Eur J Phys Rehabil Med</i>. 2008;44(1):87-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/18385632/pubmed" id="18385632" target="_blank">18385632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32450156">
<a name="32450156"></a>Chauvin KJ, Blake PG, Garg AX, et al. Baclofen has a risk of encephalopathy in older adults receiving dialysis. <i>Kidney Int</i>. 2020;S0085-2538(20)30552-4. doi:10.1016/j.kint.2020.04.047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/32450156/pubmed" id="32450156" target="_blank">32450156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9391686">
<a name="9391686"></a>Chen KS, Bullard MJ, Chien YY, Lee SY. Baclofen toxicity in patients with severely impaired renal function. <i>Ann Pharmacother</i>. 1997;31(11):1315-1320. doi:10.1177/106002809703101108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/9391686/pubmed" id="9391686" target="_blank">9391686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12739836">
<a name="12739836"></a>Chen YC, Chang CT, Fang JT, Huang CC. Baclofen neurotoxicity in uremic patients: is continuous ambulatory peritoneal dialysis less effective than intermittent hemodialysis? <i>Ren Fail</i>. 2009;25(2):297-305. doi:10.1081/jdi-120018730<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/12739836/pubmed" id="12739836" target="_blank">12739836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11124626">
<a name="11124626"></a>Choo YM, Kim GB, Choi JY, et al. Severe respiratory depression by low-dose baclofen in the treatment of chronic hiccups in a patient undergoing CAPD. <i>Nephron</i>. 2000;86(4):546-547. doi:10.1159/000045866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/11124626/pubmed" id="11124626" target="_blank">11124626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17195438">
<a name="17195438"></a>Chou CL, Chen CA, Lin SH, Huang HH. Baclofen-induced neurotoxicity in chronic renal failure patients with intractable hiccups. <i>South Med J</i>. 2006;99(11):1308-1309. doi:10.1097/01.smj.0000247632.84949.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/17195438/pubmed" id="17195438" target="_blank">17195438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28192790">
<a name="28192790"></a>Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. <i>Ann Intern Med</i>. 2017;166(7):480-492. doi:10.7326/M16-2458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/28192790/pubmed" id="28192790" target="_blank">28192790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CSM.1997">
<a name="CSM.1997"></a>Committee on Safety of Medicines (CSM), Medicines Control Agency. Reminder: severe withdrawal reactions with baclofen. <i>Curr Probl Pharmacovigilance</i>. 1997;23:1-4. <a href="https://webarchive.nationalarchives.gov.uk/20090218060434/http://www.mhra.gov.uk/home/groups/pl-p/documents/publication/con2023229.pdf" target="_blank">https://webarchive.nationalarchives.gov.uk/20090218060434/http://www.mhra.gov.uk/home/groups/pl-p/documents/publication/con2023229.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18562512">
<a name="18562512"></a>Dalton CM, Keenan E, Jarrett L, Buckley L, Stevenson VL. The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. <i>Mult Scler</i>. 2008;14(4):571-572. doi: 10.1177/1352458507085552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/18562512/pubmed" id="18562512" target="_blank">18562512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2931831">
<a name="2931831"></a>Dapas F, Hartman SF, Martinez L, et al. Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo.<i> Spine (Phila Pa 1976)</i>. 1985;10(4):345-349. doi:10.1097/00007632-198505000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/2931831/pubmed" id="2931831" target="_blank">2931831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15350152">
<a name="15350152"></a>Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. <i>Drug Saf</i>. 2004;27(11):799-818. doi:10.2165/00002018-200427110-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/15350152/pubmed" id="15350152" target="_blank">15350152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27833235">
<a name="27833235"></a>Das S, Palappalllil DS, Purushothaman ST, Rajan V. An unusual case of baclofen abuse. <i>Indian J Psychol Med</i>. 2016;38(5):475-476. doi:10.4103/0253-7176.191383<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/27833235/pubmed" id="27833235" target="_blank">27833235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9596387">
<a name="9596387"></a>Denys P, Mane M, Azouvi P, Chartier-Kastler E, Thiebaut JB, Bussel B. Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. <i>Arch Phys Med Rehabil</i>. 1998;79(5):494-496. doi:10.1016/s0003-9993(98)90061-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/9596387/pubmed" id="9596387" target="_blank">9596387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23536044">
<a name="23536044"></a>Duncan SD, Devlin LA. Use of baclofen for withdrawal in a preterm infant. <i>J Perinatol</i>. 2013;33(4):327-328. doi:10.1038/jp.2012.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/23536044/pubmed" id="23536044" target="_blank">23536044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22041434">
<a name="22041434"></a>El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A. Baclofen toxicity in patients with advanced nephropathy: proposal for new labeling. <i>Am J Nephrol</i>. 2011;34(6):491-495. doi:10.1159/000333247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/22041434/pubmed" id="22041434" target="_blank">22041434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7313501">
<a name="7313501"></a>Eriksson G, Swahn CG. Concentrations of baclofen in serum and breast milk from a lactating woman. <i>Scand J Clin Lab Invest</i>. 1981;41(2):185-187. doi:10.3109/00365518109092032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/7313501/pubmed" id="7313501" target="_blank">7313501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Azurity.1">
<a name="Azurity.1"></a>Fleqsuvy (baclofen) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26810267">
<a name="26810267"></a>Freeman EH, Delaney RM. Neonatal baclofen withdrawal: A case report of an infant presenting with severe feeding difficulties. <i>J Pediatr Nurs</i>. 2016;31(3):346-349. doi:10.1016/j.pedn.2015.12.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/26810267/pubmed" id="26810267" target="_blank">26810267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gablofen.2019.12">
<a name="Gablofen.2019.12"></a>Gablofen (baclofen) [prescribing information]. Bethlehem, PA: Primal Critical Care Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Galvez-Jimenez.2020">
<a name="Galvez-Jimenez.2020"></a>Galvez-Jimenez N. Symptom-based management of amyotrophic lateral sclerosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31110881">
<a name="31110881"></a>Gee SW, Outsen S, Becknell B, Schwaderer AL. Baclofen toxicity responsive to hemodialysis in a pediatric patient with acute kidney injury. <i>J Pediatr Intensive Care</i>. 2016;5(1):37-40. doi:10.1055/s-0035-1568151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/31110881/pubmed" id="31110881" target="_blank">31110881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28449569">
<a name="28449569"></a>Ghosh S, Bhuyan D. Baclofen abuse due to its hypomanic effect in patients with alcohol dependence and comorbid major depressive disorder. <i>Clin Psychopharmacol Neurosci</i>. 2017;15(2):187-189. doi:10.9758/cpn.2017.15.2.187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/28449569/pubmed" id="28449569" target="_blank">28449569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18007255">
<a name="18007255"></a>Ginsburg GM, Lauder AJ. Progression of scoliosis in patients with spastic quadriplegia after the insertion of an intrathecal baclofen pump. <i>Spine (Phila Pa 1976)</i>. 2007;32(24):2745-2750. doi:10.1097/BRS.0b013e31815a5219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/18007255/pubmed" id="18007255" target="_blank">18007255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27504360">
<a name="27504360"></a>Goyal V, Laisram N, Wadhwa RK, Kothari SY. Prospective randomized study of oral diazepam and baclofen on spasticity in cerebral palsy. <i>J Clin Diagn Res</i>. 2016;10(6):RC01-RC5. doi:10.7860/JCDR/2016/17067.7975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/27504360/pubmed" id="27504360" target="_blank">27504360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18349207">
<a name="18349207"></a>Grande LA, Loeser JD, Samii A. Recurrent transient global amnesia with intrathecal baclofen. <i>Anesth Analg</i>. 2008;106(4):1284-1287, table of contents. doi:10.1213/ane.0b013e318165e1c6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/18349207/pubmed" id="18349207" target="_blank">18349207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1865216">
<a name="1865216"></a>Grant JA, Steiner EM, Johnson RH. Treatment of persistent hiccups. <i>J Neurol Neurosurg Psychiatry</i>. 1991;54(5):468. doi:10.1136/jnnp.54.5.468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/1865216/pubmed" id="1865216" target="_blank">1865216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12645974">
<a name="12645974"></a>Greenberg MI, Hendrickson RG. Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement. <i>J Toxicol Clin Toxicol</i>. 2003;41(1):83-85. doi:10.1081/clt-120018277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/12645974/pubmed" id="12645974" target="_blank">12645974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7758557">
<a name="7758557"></a>Guelaud C, Similowski T, Bizec JL, Cabane J, Whitelaw WA, Derenne JP. Baclofen therapy for chronic hiccup. <i>Eur Respir J</i>. 1995;8(2):235-237. doi:10.1183/09031936.95.08020235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/7758557/pubmed" id="7758557" target="_blank">7758557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11684810">
<a name="11684810"></a>Hadjiyannacos D, Vlassopoulos D, Hadjiconstantinou V. Treatment of intractable hiccup in haemodialysis patients with baclofen. <i>Am J Nephrol</i>. 2001;21(5):427-8. doi:10.1159/000046290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/11684810/pubmed" id="11684810" target="_blank">11684810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30023142">
<a name="30023142"></a>Hara T, Nakajima M, Sugano H, et al. Pregnancy and breastfeeding during intrathecal baclofen therapy - a case study and review. <i>NMC Case Rep J</i>. 2018;5(3):65-68. doi:10.2176/nmccrj.cr.2017-0191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/30023142/pubmed" id="30023142" target="_blank">30023142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-He.2014">
<a name="He.2014"></a>He Y, Brunstrom-Hernandez JE, Thio LL, et al. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. <i>J Pediatr</i>. 2014;164(5):1181-1188.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11305407">
<a name="11305407"></a>Hemingway C, McGrogan J, Freeman JM. Energy requirements of spasticity. <i>Dev Med Child Neurol</i>. 2001;43(4):277-278. doi:10.1017/s0012162201000524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/11305407/pubmed" id="11305407" target="_blank">11305407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hornyak.1">
<a name="Hornyak.1"></a>Hornyak JE, McGehee MJ, Kelly B, Lin C. Oral baclofen as a cause of sexual dysfunction: A report of 2 cases. <i>Archives of Physical Medicine and Rehabilitation</i>. 2005;86(9):E39, Poster 197. https://www.archives-pmr.org/action/showPdf?pii=S0003-9993%2805%2900809-9
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isaac.2020">
<a name="Isaac.2020"></a>Isaac Z. Management of non-radicular neck pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353141">
<a name="21353141"></a>Karol DE, Muzyk AJ, Preud'homme XA. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. <i>Gen Hosp Psychiatry</i>. 2011;33(1):84.e1-e2. doi:10.1016/j.genhosppsych.2010.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/21353141/pubmed" id="21353141" target="_blank">21353141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26312004">
<a name="26312004"></a>Karthikeyan VS, Senthilkumaran K, Easwaran B, Rajbhaskar R. Intestinal pseudo-obstruction following oral baclofen: An unusual complication. <i>J Pharmacol Pharmacother</i>. 2015;6(3):169-171. doi:10.4103/0976-500X.162010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/26312004/pubmed" id="26312004" target="_blank">26312004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11051387">
<a name="11051387"></a>Katsinelos P, Pilpilidis J, Xiarchos P, et al. Baclofen therapy for intractable hiccups induced by ultraflex esophageal endoprosthesis. <i>Am J Gastroenterol</i>. 2000;95(10):2986-2987. doi:10.1111/j.1572-0241.2000.03216.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/11051387/pubmed" id="11051387" target="_blank">11051387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30537935">
<a name="30537935"></a>Khazneh E, Shamlawi A, Jebrin K, Hamdan Z, Sawalmeh O. Single-dose baclofen-induced neurotoxicity in a patient with end stage renal disease: case report. <i>BMC Nephrol</i>. 2018;19(1):352. doi:10.1186/s12882-018-1167-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/30537935/pubmed" id="30537935" target="_blank">30537935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23682655">
<a name="23682655"></a>Lee J, Shin HS, Jung YS, Rim H. Two cases of baclofen-induced encephalopathy in hemodialysis and peritoneal dialysis patients. <i>Ren Fail</i>. 2013;35(6):860-862. doi:10.3109/0886022X.2013.794679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/23682655/pubmed" id="23682655" target="_blank">23682655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lin.2014">
<a name="Lin.2014"></a>Lin HH, Barton N, Wiegand TJ. Baclofen distribution into breast milk - a potential for toxicity? <i>J Med Toxicol</i>. 2014;10:86.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lioresal.2019.01">
<a name="Lioresal.2019.01"></a>Lioresal Intrathecal (baclofen) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LioresalIntrathecal.2020.05">
<a name="LioresalIntrathecal.2020.05"></a>Lioresal Intrathecal (baclofen) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LioresalTablets.2020.05">
<a name="LioresalTablets.2020.05"></a>Lioresal tablets (baclofen) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30736882">
<a name="30736882"></a>Locatelli F, Formica F, Galbiati S, et al. Polysomnographic analysis of a pediatric case of baclofen-induced central sleep apnea. <i>J Clin Sleep Med</i>. 2019;15(2):351-354. doi:10.5664/jcsm.7644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/30736882/pubmed" id="30736882" target="_blank">30736882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17091060">
<a name="17091060"></a>Lois F, Wallemacq P, de Tourtchaninoff M, et al. Prolonged unconsciousness in a patient on automated peritoneal dialysis. <i>Eur J Emerg Med</i>. 2006;13(6):361-363. doi:10.1097/01.mej.0000217992.32235.ff<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/17091060/pubmed" id="17091060" target="_blank">17091060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17156708">
<a name="17156708"></a>Lubsch L, Habersang R, Haase M, Luedtke S. Oral baclofen and clonidine for treatment of spasticity in children. <i>J Child Neurol</i>. 2006;21(12):1090-1092. doi:10.1177/7010.2006.00134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/17156708/pubmed" id="17156708" target="_blank">17156708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saol.1">
<a name="Saol.1"></a>Lyvispah (baclofen) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9772082">
<a name="9772082"></a>Marino RA. Baclofen therapy for intractable hiccups in pancreatic carcinoma. <i>Am J Gastroenterol</i>. 1998;93(10):2000. doi: 10.1111/j.1572-0241.1998.02000.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/9772082/pubmed" id="9772082" target="_blank">9772082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17000991">
<a name="17000991"></a>McGehee M, Hornyak JE, Lin C, Kelly BM. Baclofen-induced sexual dysfunction. <i>Neurology</i>. 2006;67(6):1097-1098. doi:10.1212/01.wnl.0000237332.25528.ac<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/17000991/pubmed" id="17000991" target="_blank">17000991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23074476">
<a name="23074476"></a>Medical Advisory Secretariat. Intrathecal baclofen pump for spasticity: an evidence-based analysis. <i>Ont Health Technol Assess Ser</i>. 2005;5(7):1-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/23074476/pubmed" id="23074476" target="_blank">23074476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24851698">
<a name="24851698"></a>Méndez-Lucena C, Chacón Peña J, García-Moreno JM. Intrathecal baclofen for dystonia treatment during pregnancy: a case report. <i>Neurologia</i>. 2016;31(2):131-132. doi:10.1016/j.nrl.2014.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/24851698/pubmed" id="24851698" target="_blank">24851698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25567218">
<a name="25567218"></a>Meulendijks D, Khan S, Koks CH, Huitema AD, Schellens JH, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. <i>Eur J Clin Pharmacol</i>. 2015;71(3):357-361. doi:10.1007/s00228-014-1802-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/25567218/pubmed" id="25567218" target="_blank">25567218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-338390">
<a name="338390"></a>Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. <i>J Int Med Res</i>. 1977;5(6):398-404. doi:10.1177/030006057300100203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/338390/pubmed" id="338390" target="_blank">338390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23834241">
<a name="23834241"></a>Mirijello A, Addolorato G, D'Angelo C, et al. Baclofen in the treatment of persistent hiccup: a case series. <i>Int J Clin Pract</i>. 2013;67(9):918-921. doi:10.1111/ijcp.12184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/23834241/pubmed" id="23834241" target="_blank">23834241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15301690">
<a name="15301690"></a>Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: a case report. <i>BMC Clin Pharmacol</i>. 2004;4:6. doi:10.1186/1472-6904-4-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/15301690/pubmed" id="15301690" target="_blank">15301690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17378237">
<a name="17378237"></a>Morant A, Noé E, Boyer J, et al. Paralytic ileus: a complication after intrathecal baclofen therapy. <i>Brain Inj</i>. 2006;20(13-14):1451-1454. doi:10.1080/02699050601082016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/17378237/pubmed" id="17378237" target="_blank">17378237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19942189">
<a name="19942189"></a>Morton CM, Rosenow J, Wong C, Kirschner KL. Intrathecal baclofen administration during pregnancy: a case series and focused clinical review. <i>PM R</i>. 2009;1(11):1025-1029. doi:10.1016/j.pmrj.2009.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/19942189/pubmed" id="19942189" target="_blank">19942189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Olek.2020">
<a name="Olek.2020"></a>Olek MJ, Narayan RM, Frohman EM, Frohman TC. Symptom management of multiple sclerosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27157226">
<a name="27157226"></a>Olivier PY, Joyeux-Faure M, Gentina T, et al. Severe central sleep apnea associated with chronic baclofen therapy: A case series. <i>Chest</i>. 2016;149(5):e127-e131. doi:10.1016/j.chest.2015.10.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/27157226/pubmed" id="27157226" target="_blank">27157226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11597980">
<a name="11597980"></a>O'Rourke F, Steinberg R, Ghosh P, Khan S. Withdrawal of baclofen may cause acute confusion in elderly patients. <i>BMJ</i>. 2001;323(7317):870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/11597980/pubmed" id="11597980" target="_blank">11597980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ozobax.2019.09">
<a name="Ozobax.2019.09"></a>Ozobax (baclofen) [prescribing information]. Athens, GA: Metacel Pharmaceuticals LLC; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ozobax.2019.09">
<a name="Ozobax.2019.09"></a>Ozobax DS (baclofen) [prescribing information]. Athens, GA: Metacel Pharmaceuticals LLC; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31733394">
<a name="31733394"></a>Panagopoulos D, Apostolopoulou K, Themistocleous M. Severe neuromuscular scoliosis implicated by dysfunction of intrathecal baclofen pump: Case report and review of the literature. <i>World Neurosurg</i>. 2020;134:390-395. doi:10.1016/j.wneu.2019.11.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/31733394/pubmed" id="31733394" target="_blank">31733394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31384209">
<a name="31384209"></a>Pathak LK, Athavale A, Martinez I. Baclofen-induced toxicity in renal disease with neurotoxicity and skin rash. <i>Proc (Bayl Univ Med Cent)</i>. 2019;32(3):425-426. doi:10.1080/08998280.2019.1618659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/31384209/pubmed" id="31384209" target="_blank">31384209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9681766">
<a name="9681766"></a>Peces R, Navascués RA, Baltar J, Laurés AS, Alvarez-Grande J. Baclofen neurotoxicity in chronic haemodialysis patients with hiccups. <i>Nephrol Dial Transplant</i>. 1998;13(7):1896-1897.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/9681766/pubmed" id="9681766" target="_blank">9681766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28152635">
<a name="28152635"></a>Pelissier F, de Haro L, Cardona F, et al. Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013. <i>Clin Toxicol (Phila)</i>. 2017;55(4):275-284. doi:10.1080/15563650.2017.1284330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/28152635/pubmed" id="28152635" target="_blank">28152635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27789113">
<a name="27789113"></a>Porter LM, Merrick SS, Katz KD. Baclofen toxicity in a patient with hemodialysis-dependent end-stage renal disease. <i>J Emerg Med</i>. 2017;52(4):e99-e100. doi:10.1016/j.jemermed.2016.09.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/27789113/pubmed" id="27789113" target="_blank">27789113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101040">
<a name="20101040"></a>Quality Standards Subcommittee of the American Academy of Neurology (AAN) and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <i>Neurology</i>. 2010;74(4):336-343. doi: 10.1212/WNL.0b013e3181cbcd2f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/20101040/pubmed" id="20101040" target="_blank">20101040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11451783">
<a name="11451783"></a>Ratnayaka BD, Dhaliwal H, Watkin S. Drug points: Neonatal convulsions after withdrawal of baclofen. <i>BMJ</i>. 2001;323(7304):85. doi:10.1136/bmj.323.7304.85<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/11451783/pubmed" id="11451783" target="_blank">11451783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31851884">
<a name="31851884"></a>Reis PV, Vieira CR, Midões AC, Rebelo V, Barbosa P, Gomes A. Intrathecal baclofen infusion pumps in the treatment of spasticity: A retrospective cohort study in a Portuguese Centre. <i>Acta Med Port</i>. 2019;32(12):754-759. doi:10.20344/amp.10482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/31851884/pubmed" id="31851884" target="_blank">31851884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21725173">
<a name="21725173"></a>Rifici C, D'Aleo G, D'Aleo P, Bramanti P, Saltuari L, Kofler M. Cardiovascular alterations heralded by intrathecal baclofen bolus. <i>NeuroRehabilitation</i>. 2011;28(4):389-393. doi:10.3233/NRE-2011-0668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/21725173/pubmed" id="21725173" target="_blank">21725173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LabRiva.1">
<a name="LabRiva.1"></a>Riva-baclofen (baclofen) [product monograph]. Blainville, Canada: Laboratoire Riva Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096760">
<a name="26096760"></a>Roberts JK, Westphal S, Sparks MA. Iatrogenic Baclofen neurotoxicity in ESRD: recognition and management. <i>Semin Dial</i>. 2015;28(5):525-529. doi:10.1111/sdi.12400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/26096760/pubmed" id="26096760" target="_blank">26096760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21119092">
<a name="21119092"></a>Saddichha S, Jayaram N, Manjunatha N, Benegal V. Baclofen-induced morbiliform rashes: a case series. <i>J Clin Pharmacol</i>. 2011;51(12):1733-1734. doi:10.1177/0091270010385936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/21119092/pubmed" id="21119092" target="_blank">21119092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Salim SA, Thomas L, Achanti A, et al. Baclofen-induced neurotoxicity in patients with compromised renal function: Review. <i>Int J Clin Pharmacol Ther</i>. 2018;56(10):467-475. doi:10.5414/CP203243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27434299">
<a name="27434299"></a>Saulino M, Anderson DJ, Doble J, et al. Best practices for intrathecal baclofen therapy: Troubleshooting. <i>Neuromodulation</i>. 2016;19(6):632-641. doi:10.1111/ner.12467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/27434299/pubmed" id="27434299" target="_blank">27434299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18533420">
<a name="18533420"></a>Saval A, Chiodo AE. Sexual dysfunction associated with intrathecal baclofen use: a report of two cases. <i>J Spinal Cord Med</i>. 2008;31(1):103-105. doi:10.1080/10790268.2008.11753989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/18533420/pubmed" id="18533420" target="_blank">18533420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17044900">
<a name="17044900"></a>Scheinberg A, Hall K, Lam LT, O'Flaherty S. Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. <i>J Paediatr Child Health</i>. 2006;42(11):715-20. doi:10.1111/j.1440-1754.2006.00957.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/17044900/pubmed" id="17044900" target="_blank">17044900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26411756">
<a name="26411756"></a>Sechrist C, Kinsman S, Cain N. Profound bradycardia after intrathecal baclofen injection in a patient with hydranencephaly. <i>Pediatr Neurol</i>. 2015;53(6):532-534. doi:10.1016/j.pediatrneurol.2015.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/26411756/pubmed" id="26411756" target="_blank">26411756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21442315">
<a name="21442315"></a>Seker MM, Aksoy S, Ozdemir NY, et al. Successful treatment of chronic hiccup with baclofen in cancer patients. <i>Med Oncol</i>. 2012;29(2):1369-1370. doi:10.1007/s12032-011-9910-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/21442315/pubmed" id="21442315" target="_blank">21442315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1443727">
<a name="1443727"></a>Siegfried RN, Jacobson L, Chabal C. Development of an acute withdrawal syndrome following the cessation of intrathecal baclofen in a patient with spasticity. <i>Anesthesiology</i>. 1992;77(5):1048-1050. doi:10.1097/00000542-199211000-00034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/1443727/pubmed" id="1443727" target="_blank">1443727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21686448">
<a name="21686448"></a>Singh NK, Agarwal A, Salazar L, Henkle JQ. Osborn waves in hypothermia induced by baclofen overdose. <i>BMJ Case Rep</i>. 2009;2009:bcr10.2008.1142. doi:10.1136/bcr.10.2008.1142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/21686448/pubmed" id="21686448" target="_blank">21686448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20044395">
<a name="20044395"></a>Su W, Yegappan C, Carlisle EJ, Clase CM. Reduced level of consciousness from baclofen in people with low kidney function. <i>BMJ</i>. 2009;339:b4559. doi:10.1136/bmj.b4559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/20044395/pubmed" id="20044395" target="_blank">20044395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3731773">
<a name="3731773"></a>Swigar ME, Bowers MB. Baclofen withdrawal and neuropsychiatric symptoms: a case report and review of other case literature. <i>Compr Psychiatry</i>. 1986;27(4):396-400. doi:10.1016/0010-440x(86)90016-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/3731773/pubmed" id="3731773" target="_blank">3731773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27576877">
<a name="27576877"></a>Tandon SS, Hoskins I, Azhar S. Intrathecal baclofen pump - a viable therapeutic option in pregnancy. <i>Obstet Med</i>. 2010;3(3):119-120. doi:10.1258/om.2010.100016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/27576877/pubmed" id="27576877" target="_blank">27576877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18154840">
<a name="18154840"></a>Turkyilmaz A, Eroglu A. Use of baclofen in the treatment of esophageal stent-related hiccups. <i>Ann Thorac Surg</i>. 2008;85(1):328-330. doi:10.1016/j.athoracsur.2007.07.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/18154840/pubmed" id="18154840" target="_blank">18154840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12973146">
<a name="12973146"></a>van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM; Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration. <i>Spine (Phila Pa 1976)</i>. 2003;28(17):1978-1992. doi:10.1097/01.BRS.0000090503.38830.AD<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/12973146/pubmed" id="12973146" target="_blank">12973146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24414993">
<a name="24414993"></a>Vlavonou R, Perreault MM, Barrière O, et al. Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations. <i>J Clin Pharmacol</i>. 2014;54(5):584-592. doi:10.1002/jcph.247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/24414993/pubmed" id="24414993" target="_blank">24414993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29050720">
<a name="29050720"></a>Walker KR, Novotny SA, Krach LE. Does intrathecal baclofen therapy increase prevalence and/or progression of neuromuscular scoliosis? <i>Spine Deform</i>. 2017;5(6):424-429. doi:10.1016/j.jspd.2017.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/29050720/pubmed" id="29050720" target="_blank">29050720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22729246">
<a name="22729246"></a>Weißhaar GF, Hoemberg M, Bender K, et al. Baclofen intoxication: a "fun drug" causing deep coma and nonconvulsive status epilepticus--a case report and review of the literature. <i>Eur J Pediatr</i>. 2012;171(10):1541-1547. doi:10.1007/s00431-012-1780-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/22729246/pubmed" id="22729246" target="_blank">22729246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28899601">
<a name="28899601"></a>Wolf E, Kothari NR, Roberts JK, Sparks MA. Baclofen toxicity in kidney disease. <i>Am J Kidney Dis</i>. 2018;71(2):275-280. doi:10.1053/j.ajkd.2017.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/28899601/pubmed" id="28899601" target="_blank">28899601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15615812">
<a name="15615812"></a>Wu VC, Lin SL, Lin SM, Fang CC. Treatment of baclofen overdose by haemodialysis: a pharmacokinetic study. <i>Nephrol Dial Transplant</i>. 2005;20(2):441-443. doi:10.1093/ndt/gfh297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/15615812/pubmed" id="15615812" target="_blank">15615812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23129445">
<a name="23129445"></a>Yang TF, Wang JC, Chiu JW, Lai CJ, Chan RC, Lee SS. Ultrasound-guided refilling of an intrathecal baclofen pump--a case report. <i>Childs Nerv Syst</i>. 2013;29(2):347-349. doi: 10.1007/s00381-012-1953-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/23129445/pubmed" id="23129445" target="_blank">23129445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26599496">
<a name="26599496"></a>Zeman A, Hoefeijzers S, Milton F, Dewar M, Carr M, Streatfield C. The GABAB receptor agonist, baclofen, contributes to three distinct varieties of amnesia in the human brain - A detailed case report. <i>Cortex</i>. 2016;74:9-19. doi:10.1016/j.cortex.2015.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/26599496/pubmed" id="26599496" target="_blank">26599496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25052238">
<a name="25052238"></a>Zhang C, Zhang R, Zhang S, Xu M, Zhang S. Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. <i>Trials</i>. 2014;15:295. doi:10.1186/1745-6215-15-295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/baclofen-pediatric-drug-information/abstract-text/25052238/pubmed" id="25052238" target="_blank">25052238</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12983 Version 705.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
